Literature DB >> 33241228

Unconventional multidisciplinary team strategy for tracheostomy in COVID-19.

T G Smith1,2, I Ahmad1,3, A Takhar4, P Surda4, K El-Boghdadly1,3.   

Abstract

Entities:  

Keywords:  COVID‐19; aerosolisation; airway management; multidisciplinary team; percutaneous tracheostomy

Year:  2020        PMID: 33241228      PMCID: PMC7671090          DOI: 10.1002/anr3.12074

Source DB:  PubMed          Journal:  Anaesth Rep        ISSN: 2637-3726


× No keyword cloud information.
The approach an institution takes to tracheostomy during the coronavirus disease 2019 (COVID‐19) pandemic has broad potential to influence morbidity and mortality, as tracheostomy is at the intersection of patient‐centred care, healthcare worker safety and resource allocation [1]. Consensus guidance is, by necessity, based largely on expert opinion, and real‐world experience is required [1]. We have accumulated extensive experience using an unconventional multidisciplinary team strategy in which percutaneous dilatational tracheostomy is undertaken at the bed‐side in open intensive care units (ICUs) by teams combining anaesthetists and surgeons. In the context of a strained critical care system, greater resource efficiency is a crucial benefit of this approach. Our institution has been at the epicentre of the UK pandemic, admitting hundreds of patients to regular and ‘surge’ ICUs. There has been a very high requirement for tracheal intubation and mechanical ventilation, and subsequently for tracheostomy. We established mobile emergency rapid intubation teams (MERIT) early in the pandemic response, which follow specific protocols for personal protective equipment (PPE) and minimising aerosol generation and thus operator risk of infection [2]. Mobile emergency rapid intubation teams, consisting of two consultant anaesthetists and two assistants, are responsible for all COVID‐19 tracheal intubations in the hospital [3]. Our key multidisciplinary innovation was to then develop a dedicated tracheostomy team comprising two ear, nose and throat (ENT) surgeons and two MERIT anaesthetists. To our knowledge, we were the first UK centre to develop such teams and publish guidelines for tracheostomy in COVID‐19 including procedures for PPE, minimising aerosolisation and improved success with minimal complications [4]. ENT surgeons have been involved in ‘surge’ tracheostomy strategies in other centres, for example, instituting a dedicated tracheostomy theatre. However, our approach was distinct and unusual both in combining ENT surgeons with anaesthetists to form a tracheostomy team and, crucially, in this team undertaking percutaneous tracheostomies independently at the bed‐side in the ICU. This was in contrast to normal practice where tracheostomies would be inserted either by ICU operators alone, or alternatively in the operating theatre as a surgical tracheostomy. The ENT/MERIT tracheostomy team has quickly developed expertise in using advanced PPE and minimising aerosolisation in accordance with carefully devised procedures including a step‐by‐step protocol for bed‐side tracheostomy (Fig. 1). This protocol includes the use of ultrasound to identify structures and mark a ‘never above’ line to minimise the risk of damaging the tracheal tube cuff, as well as videolaryngoscopy to view the tracheal tube cuff and fibreoptic bronchoscopy for internal viewing. Our self‐contained team model promotes efficient use of personnel and resources by relieving ICU staff and avoiding ICU‐theatre transfers. At our institution, it has also exploited changing capacity of MERIT anaesthetists as the requirement for tracheostomies has progressively overtaken primary intubations. Outcomes from our first 28 tracheostomies have been favourable with no significant complications or deaths, and no operators have developed COVID‐19 (GSTT service evaluation ID 10780; Table 1).
Figure 1

Anaesthetic management for percutaneous tracheostomy insertion in COVID‐19 at Guy's and St Thomas' NHS Foundation Trust. (a) Trust's action card including step‐by‐step protocol, minimum equipment list and instructions for ultrasound markings. (b) Schematic for measuring structures using ultrasound and marking a ‘never above’ line to minimise the risk of damaging the tracheal tube cuff.

Table 1

Data from 28 patients with COVID‐19 undergoing percutaneous tracheostomy in ICU by dedicated multidisciplinary teams.

VariableMedian (IQR [range]) or n (%)
Age (years)55 (48–61 [28–78])
Sex
Male18 (64%)
Female10 (36%)
Ethnicity
Black, Asian or minority ethnic group20 (71%)
White8 (29%)
Weight (kg)76 (72–95 [55–118])
Height (m)1.75 (1.65–1.79 [1.52–1.93])
Body mass index (kg.m−2)29 (24–31 [22–40])
APACHE II score on admission13 (12–16 [8–19])
Timing of tracheostomy (days post‐intubation)19 (14–24 [6–31])
Respiratory status at time of tracheostomy
PEEP (cmH2O)8 (6–8 [5–10])
FiO2 (%)0.35 (0.30–0.40 [0.21–0.55])
PaO2 (mmHg)72 (68–79 [59–102])
P/F ratio207 (183–246 [144–379])
Duration of follow‐up (days post‐tracheostomy)40 (45–49 [9–70])
Patient status at follow‐up
Alive28 (100%)
Discharged from ICU24 (86%)
Decannulated24 (86%)
Discharged from hospital18 (64%)
Days from tracheostomy to
Discharge from ICU20 (13–28 [4–48])
Decannulation18 (14–30 [9–46])
Discharge from hospital37 (28–45 [13–63])
Significant complications from tracheostomy* 0 (0%)
Transmission of COVID‐19 to operators0 (0%)
Mortality0 (0%)

*Significant complications are defined as Clavien‐Dindo Grade 2 or higher.

APACHE II, acute physiology and chronic health evaluation II score; FiO2, fraction of inspired oxygen; PaO2, arterial partial pressure of oxygen; PEEP, positive end‐expiratory pressure; P/F ratio, PaO2/FiO2 ratio.

Anaesthetic management for percutaneous tracheostomy insertion in COVID‐19 at Guy's and St Thomas' NHS Foundation Trust. (a) Trust's action card including step‐by‐step protocol, minimum equipment list and instructions for ultrasound markings. (b) Schematic for measuring structures using ultrasound and marking a ‘never above’ line to minimise the risk of damaging the tracheal tube cuff. Data from 28 patients with COVID‐19 undergoing percutaneous tracheostomy in ICU by dedicated multidisciplinary teams. *Significant complications are defined as Clavien‐Dindo Grade 2 or higher. APACHE II, acute physiology and chronic health evaluation II score; FiO2, fraction of inspired oxygen; PaO2, arterial partial pressure of oxygen; PEEP, positive end‐expiratory pressure; P/F ratio, PaO2/FiO2 ratio. The presence of ENT surgeons in the team may have allowed more challenging tracheostomies that would not normally be attempted in ICU (e.g. obese patients) to still be undertaken in the most resource‐efficient manner. While the ideal location for performing a tracheostomy on a COVID‐19‐positive patient is in a negative pressure side room or operating theatre, this may not be available, and transferring critically ill patients to theatre also has major resource and safety implications. Recent preliminary data from a national UK audit (UK COVIDTrach) indicate that percutaneous tracheostomy is at least as safe as surgical tracheostomy in COVID‐19 [5]. Anecdotally, percutaneous tracheostomies may be less prone to wound site infections and dislodgement in the presence of thick tenacious secretions in COVID‐19. Until further data are forthcoming, we recommend consideration of this multidisciplinary team model and protocol for tracheostomy in COVID‐19 in order to deliver safe patient‐centred care and support healthcare worker safety while simultaneously optimising the balance between these priorities and the efficient utilisation of scarce resources.
  4 in total

1.  Awake tracheal intubation in a suspected COVID-19 patient with critical airway obstruction.

Authors:  I Ahmad; S Wade; A Langdon; H Chamarette; M Walsh; P Surda
Journal:  Anaesth Rep       Date:  2020-05-04

Review 2.  Tracheostomy in the COVID-19 era: global and multidisciplinary guidance.

Authors:  Brendan A McGrath; Michael J Brenner; Stephen J Warrillow; Vinciya Pandian; Asit Arora; Tanis S Cameron; José Manuel Añon; Gonzalo Hernández Martínez; Robert D Truog; Susan D Block; Grace C Y Lui; Christine McDonald; Christopher H Rassekh; Joshua Atkins; Li Qiang; Sébastien Vergez; Pavel Dulguerov; Johannes Zenk; Massimo Antonelli; Paolo Pelosi; Brian K Walsh; Erin Ward; You Shang; Stefano Gasparini; Abele Donati; Mervyn Singer; Peter J M Openshaw; Neil Tolley; Howard Markel; David J Feller-Kopman
Journal:  Lancet Respir Med       Date:  2020-05-15       Impact factor: 30.700

Review 3.  Recommendation of a practical guideline for safe tracheostomy during the COVID-19 pandemic.

Authors:  Arunjit Takhar; Abigail Walker; Stephen Tricklebank; Duncan Wyncoll; Nicholas Hart; Tony Jacob; Asit Arora; Christopher Skilbeck; Ricard Simo; Pavol Surda
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-04-21       Impact factor: 2.503

4.  A prospective, observational, cohort study of airway management of patients with COVID-19 by specialist tracheal intubation teams.

Authors:  Imran Ahmad; Jeyanjali Jeyarajah; Ganeshkrishna Nair; Sophie C Ragbourne; Benjamin Vowles; Danny J N Wong; Kariem El-Boghdadly
Journal:  Can J Anaesth       Date:  2020-09-04       Impact factor: 6.713

  4 in total
  2 in total

1.  Case reports in the COVID-19 pandemic: first responders to an emergency in evidence-based medicine.

Authors:  R Kearsley; R Daly Guris; L F Miles; C L Shelton
Journal:  Anaesth Rep       Date:  2021-01-11

Review 2.  Systematic review and meta-analysis of tracheostomy outcomes in COVID-19 patients.

Authors:  A Ferro; S Kotecha; G Auzinger; E Yeung; K Fan
Journal:  Br J Oral Maxillofac Surg       Date:  2021-05-18       Impact factor: 1.651

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.